Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
News|Articles|June 6, 2005
New product newswire
From GlaxoSmithKline, Research Triangle Park, N.C., (919) 483-2100, comes Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed [Tdap]). The product is indicated as a booster vaccine to be given as a single dose to patients aged 10 to 18. This booster adds a pertussis component to the tetanus/diphtheria booster routinely administered to teens.
Advertisement
Advertisement
Related to this article
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
Advertisement
Advertisement
Trending on Drug Topics
1
Serotype 34 Causes Pneumococcal Meningitis in Child With Cochlear Implants
2
FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia
3
American Pharmacists Month: The Many Career Paths US Pharmacists Explore
4
Indoor Air Sampling Could Revolutionize Pneumococcal Disease Surveillance
5